Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM) Meeting Abstract
| Authors: | Middleton, M. R.; Hamid, O.; Shoushtari, A. N.; Meier, F. E.; Bauer, T. M.; Salama, A. K. S.; Kirkwood, J. M.; Ascierto, P. A.; Lorigan, P.; Mauch, C.; Orloff, M. M.; Evans, T. R. J.; Abdullah, S. E.; Yuan, Y.; Mitchell, J.; Hassel, J. C. |
| Abstract Title: | Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300099 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.104 |
| Notes: | Meeting Abstract: 104 -- Meeting also held virtually -- Source: Wos |
